Skip to main content
SpringerLink
Log in

Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Being a “classical” sequel of hemodynamic burdens (pressure and/or volume), the untoward results of left ventricular hypertrophy (LVH) were traditionally related to its underlying causes. The Framingham study was the first to demonstrate the increased independent risk associated with LVH detected by ECG and/or by echocardiography. The presence of LVH in “nonhypertensive” individuals (e.g., obese), the association of LVH with age and gender, and the possibility of genetic control of left ventricular size via “nonhemodynamic” mechanisms had underscored the importance of LVH per se as a prognostic indicator. The presence of LVH in patients with hypertensive or coronary artery disease results in a severalfold increase in risk compared to similar patients without LVH. Early studies have indicated that the presence of LVH is associated with a significantly worse prognosis in patients recovering from myocardial infarction. We have studied the effect of LVH on long-term (mean 5.5 years) mortality in patients surviving myocardial infarction registered in the SPRINT database. The LVH patients were older and had more complications during hospitalization. The 1- and 5-year mortality rates were doubled in patients with ECG-LVH. Review of the mechanisms operating in LVH reveals important changes in the anatomy and physiology of hypertrophied heart, leading to increased fibrosis, inadequate vascular growth, impaired myocardial function (systolic and diastolic), reduced coronary reserve, and abnormal electrophysiological properties. Regression of LVH by proper treatment (achieved mainly by calcium antagonists and ACE inhibitors) may correct many of the above-mentioned adverse phenomena. Whether the regression of LVH per se will lead to improved prognosis remains to be answered in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meerson FZ. The myocardium in hyperfunction, hypertrophy and heart failure.Circ Res 1969;25(Suppl II):II1-II163.

    Google Scholar 

  2. Grossman W. Cardiac hypertrophy: Useful adaptation or pathologic process?Am J Med 1980;69:576–584.

    Google Scholar 

  3. Frohlich ED, Apstein C, Chobanian AC, et al. The heart in hypertension.N Engl J Med 1992;327:998–1008.

    Google Scholar 

  4. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study.Ann Intern Med 1969;71:89–105.

    Google Scholar 

  5. Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy?Am J Cardiol 1979;44:959–963.

    Google Scholar 

  6. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease.Am J Public Health 1951;41:279–286.

    Google Scholar 

  7. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electro-cardiographic left ventricular hypertrophy and risk of coronary heart disease.Ann Intern Med 1970;72:813–822.

    Google Scholar 

  8. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy.Am J Med 1983;75:4–11.

    Google Scholar 

  9. Kreger BE, Kannel WB, Cupples LA. Electrocardiographic precursors of sudden unexplained death: The Framingham study.Circulation 1987;75(Suppl II):II22-II24.

    Google Scholar 

  10. Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham study.Circulation 1987;75(Suppl I):I26-I33.

    Google Scholar 

  11. Levy D. Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors.Ann Intern Med 1988;108:7–13.

    Google Scholar 

  12. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study.N Engl J Med 1990;322:1561–1566.

    Google Scholar 

  13. Anversa P, Ricci R, Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review.J Am Coll Cardiol 1986;7:1140–1149.

    Google Scholar 

  14. Bache RJ. Effects of hypertrophy on the coronary circulation.Prog Cardiovasc Dis 1988;31:403–440.

    Google Scholar 

  15. Maron BJ, Ferraus VJ, Roberts WC. Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy.Am J Pathol 1975;79:387–434.

    Google Scholar 

  16. Weber KT, Janick JS, Pick R, et al. Collagen in the hypertrophied, pressure overloaded myocardium.Circulation 1987;75(Suppl I):I40-I47.

    Google Scholar 

  17. Schwartzkopff B, Frenzel H, Dieckerhoff J, et al. Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis.Eur Heart J 1992;13(Suppl D):17–23.

    Google Scholar 

  18. Meerson FZ.The Failing Heart: Adaptation and Deadaptation. New York: Raven Press, 1983.

    Google Scholar 

  19. Simpson PC. Proto-oncogenes and cardiac hypertrophy.Ann Rev Physiol 1988;51:189–202.

    Google Scholar 

  20. Robertson AL, Khairallah PA. Angiotensin II: Rapid localization in nuclei of smooth and cardiac muscle.Science 1971;172:1138–1139.

    Google Scholar 

  21. Hammond GL, Lai YK, Markert CL. The molecules that initiate cardiac hypertrophy are not species-specific.Science 1982;216:529–531.

    Google Scholar 

  22. Sen S. Factors regulating myocardial hypertrophy in hypertension.Circulation 1987;75(Suppl I):I81-I84.

    Google Scholar 

  23. Duprez DA, Bauwens FR, De Buyzere ML, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension.Am J Cardiol 1993;71:17A-20A.

    Google Scholar 

  24. Bauwens FR, De Buyzere ML, De Backer TL, et al. Influence of arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension.Am J Cardiol 1991;68:925–929.

    Google Scholar 

  25. Braunwald E. Valvular heart disease. In: Braunwald E, ed.Heart Disease, 4th ed. Philadelphia: WB Saunders, 1992: 1043–1053.

    Google Scholar 

  26. Ross J. Afterload mismatch in aortic and mitral valve disease: Implications for surgical therapy.J Am Coll Cardiol 1985;5:811–826.

    Google Scholar 

  27. Devereux RB, Drayer JI, Chien S, et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension.Am J Cardiol 1984;54:592–595.

    Google Scholar 

  28. Zannad F, Voisin P, Brunotte F, Bruntz JF, Stoltz JF, Gilgenkrantz JM. Haemorheological abnormalities in arterial hypertension and their relation to cardiac hypertrophy.J Hypertens 1988;6:293–297.

    Google Scholar 

  29. Shasha SM, Kamal H, Kristal B, Galetzky G, Roguin N, Shkolnik T. Red cell filterability in cigarette smokers and its relation to cardiac hypertrophy.Atherosclerosis 1993;98:91–98.

    Google Scholar 

  30. Tarazi RC, Frohlich ED. Is reversal of cardiac hypertrophy a desirable goal in antihypertensive therapy?Circulation 1987;75(Suppl I):I113-I117.

    Google Scholar 

  31. Henquell L, Odoroff CL, Honig CR. Intercapillary distance and capillary reserve in hypertrophied rat hearts beating in situ.Circ Res 1977;41:400–408.

    Google Scholar 

  32. Vogt M, Motz W, Strauer BE. Coronary haemodynamics in hypertensive heart disease.Eur Heart J 1992;13(Suppl D):44–49.

    Google Scholar 

  33. Polese A, De Cesara N, Montorsi P, et al. Upward shift of the lower range of coronary flow auto-regulation in hypertensive patients with hypertrophy of the left ventricle.Circulation 1991;83:845–853.

    Google Scholar 

  34. Scheler S, Motz W, Strauer BE. Transient myocardial ischaemia in hypertensives: Missing link with left ventricular hypertrophy.Eur Heart J 1992;13(Suppl D):62–65.

    Google Scholar 

  35. Lüscher TF. Heterogeneity of endothelial dysfunction in hypertension.Eur Heart J 1992;13(Suppl D):50–55.

    Google Scholar 

  36. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels.Circulation 1993;87:86–93.

    Google Scholar 

  37. Scheuer J, Buttrick P. The cardiac hypertrophic response to pathologic and physiologic loads.Circulation 1987;75(Suppl I):I63-I68.

    Google Scholar 

  38. Fouad FM. Left ventricular diastolic function in hypertensive patients.Circulation 1987;75(Suppl I):I48-I55.

    Google Scholar 

  39. Swynghedauw B, Delcayre C, Cheav SL, Callens-El Amrani F. Biological basis of diastolic dysfunction of the hypertensive heart.Eur Heart J 1992;13(Suppl D):2–8.

    Google Scholar 

  40. Limas CJ, Cohn JN. Defective calcium transport by cardiac sarcoplasmic reticulum in spontaneous hypertensive rats.Circ Res 1977;40(Suppl I):I162-I169.

    Google Scholar 

  41. Aronson RS. Mechanisms of cardiac arrhythmias in ventricular hypertrophy.J Cardiovasc Electrophysiol 1991;2:249–261.

    Google Scholar 

  42. Toyoshima H, Park Y, Ishikawa Y, et al. Effect of ventricular hypertrophy on conduction velocity of activation front in ventricular myocardium.Am J Cardiol 1984;49:1938–1945.

    Google Scholar 

  43. Tritthart H, Luedcke H, Bayer R, Stiele H, Kaufman R. Right ventricular hypertrophy in the cat: An electrophysiological and anatomical study.J Mol Cell Cardiol 1975;7:163–174.

    Google Scholar 

  44. Maron BJ, Ferrans VJ. Significance of multiple intercalated discs in hypertrophied human myocardium.Am J Pathol 1973;73:81–96.

    Google Scholar 

  45. Laks MM, Morady F, Adomian BA, Swan HJC. Presence of widened and multiplied intercalated discs in the hypertrophied canine heart.Circ Res 1970;27:391–402.

    Google Scholar 

  46. Gonzalez-Fernandez RA, Altieri PI, Fernandez-Martinez T, Lugo JE. Reduction in cardiac conduction delay by angiotensin converting enzyme inhibition in hypertensive patients with left ventricular hypertrophy.Am J Hypertens 1992;5:896–899.

    Google Scholar 

  47. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy.Am J Med 1984;77:18–22.

    Google Scholar 

  48. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy.N Engl J Med 1987;317:787–792.

    Google Scholar 

  49. Messerli FH, Grodzicki T. Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death.Eur Heart J 1992;(Suppl D):66–69.

    Google Scholar 

  50. Melina D, Colivicchi F, Guerrera G, et al. Prevalence of left ventricular hypertrophy and cardiac arrhythmias in borderline hypertension.Am J Hypertens 1992;5:570–573.

    Google Scholar 

  51. Anversa P, Ricci R, Olivetti G. Effects of exercise on the capillary vasculature of the rat heart.Circulation 1987; 75(Suppl I)I12-I18.

    Google Scholar 

  52. Koyanagi S, Easthan C, Marcus ML. Effect of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs.Circulation 1982;65:1192–1197.

    Google Scholar 

  53. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension.Eur Heart J 1992;13(Suppl D):82–88.

    Google Scholar 

  54. Siegrist J, Peter R, Motz W, Strauer BE. The role of hypertension, left ventricular hypertrophy and psychosocial risks in cardiovascular disease: Prospective evidence from blue-collar men.Eur Heart J 1992;13(Suppl D):89–95.

    Google Scholar 

  55. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed.Am J Cardiol 1990;65:441–445.

    Google Scholar 

  56. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.Ann Intern Med 1991;114:345–352.

    Google Scholar 

  57. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men.Ann Intern Med 1986;105:173–178.

    Google Scholar 

  58. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease.Ann Intern Med 1992;117:831–836.

    Google Scholar 

  59. The Coronary Drug Project Research Group. Left ventricular hypertrophy pattern and prognosis. Experienced post infarction in the Coronary Drug Project.Circulation 1974;49:862–869.

    Google Scholar 

  60. Wong ND, Levy D, Kannel WB. Prognostic significance of the electrocardiogram after Q wave myocardial infarction.Circulation 1990;81:780–789.

    Google Scholar 

  61. Boden WE, Kleiger RE, Schechtman KB, Capone RJ, Schwartz DT, Gibson RS and the Diltiazem reinfarction study group: Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction.Am J Cardiol 1988;62:1000–1004.

    Google Scholar 

  62. The Israeli SPRINT Study Group. Secondary prevention of reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction.Eur Heart J 1988;9:354–364.

    Google Scholar 

  63. Behar S, Reicher-Reiss H, Abinader E, et al. Long-term prognosis after acute myocardial infarction in patients with left ventricular hypertrophy on the electrocardiogram.Am J Cardiol 1992;69:985–990.

    Google Scholar 

  64. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.Ann Intern Med 1992;117:719–726.

    Google Scholar 

  65. Maron BJ, Pelliccia A, Spataro A, Granata M. Reduction of left ventricular wall thickness after deconditioning in highly trained Olympic athletes.Br Heart J 1993;69:125–128.

    Google Scholar 

  66. Gilbert BW. ACE inhibitors and regression of left ventricular hypertrophy.Clin Cardiol 1992;15:711–714.

    Google Scholar 

  67. Vyssoulis GP, Karanou EA, Pitsavos CE, Paleologas AA, Toutouzas PK. Regression of left ventricular hypertrophy in systemic hypertension with beta blockers (propranolol, atenolol, metoprolol, pindolol and celiprolol).Am J Cardiol 1992;70:1209–1211.

    Google Scholar 

  68. Gerstenblith G. Left ventricular mass regression in elderly hypertensives.J Hum Hypertens 1992;6(Suppl 2):S15–17.

    Google Scholar 

  69. Modena MG, Mattioli AV, Parato VM, Mattiolo G. Effectiveness of the antihypertensive action of lininopril on left ventricular mass and diastolic filling.Eur Heart J 1992;13:1540–1544.

    Google Scholar 

  70. Schmieder RE. Hypertensive heart disease: Significance of left ventricular hypertrophy.J Cardiovasc Pharmacol 1992;20(Suppl 6):S50–55.

    Google Scholar 

  71. Dahlof B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: Different effects of enalapril and hydrochlorothiazide.J Hypertens 1992;10:1513–1524.

    Google Scholar 

  72. MacMahon SW, Wilcken EL, MacDonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young overweight hypertensive patients.N Engl J Med 1986;314:334–339.

    Google Scholar 

  73. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies.Am J Hypertens 1992;5:95–110.

    Google Scholar 

  74. Messerli FH, Soria F. Does reduction of left ventricular hypertrophy reduce cardiovascular morbidity and mortality?Drugs 1992;44(Suppl I):141–146.

    Google Scholar 

  75. Omotoso AB, Dunn FG. Impact of regression of left ventricular hypertrophy on cardiac function in hypertension.Eur Heart J 1992;13(Suppl D):107–110.

    Google Scholar 

  76. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy.Am J Physiol 1988;257:H1116-H1118.

    Google Scholar 

  77. Brilla CG, Maisch B, Weber KT. Myocardial collagen matrix remodeling in arterial hypertension.Eur Heart J 1992;13(Suppl D):24–32.

    Google Scholar 

  78. Messerli FH, Nunez BD, Nunez MM, Garavaglia GE, Schmeider RE, Ventura HO. Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias.Arch Intern Med 1989;149:1263–1267.

    Google Scholar 

  79. Wesseling H, de Graeff PA, van Gilst WH, Kingma JH, de Lasgen CD. Cardiac arrhythmias—a new indication for angiotensin-converting enzyme inhibitors?J Hum Hypertens 1989;3(Suppl 1):89–95.

    Google Scholar 

  80. McKenna WJ, Haywood GA. The role of ACE inhibitors in the treatment of arrhythmias.Clin Cardiol 1990;13(Suppl 7):49–52.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Institute, Sheba Medical Center, 52621, Tel-Hashomer, Israel

    Elieser Kaplinsky MD

  2. Sackler School of Medicine, Tel-Aviv University, Israel

    Elieser Kaplinsky MD

Authors
  1. Elieser Kaplinsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplinsky, E. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drug Ther 8 (Suppl 3), 549–556 (1994). https://doi.org/10.1007/BF00877223

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877223

Key Words

Search

Navigation